Loading clinical trials...
Loading clinical trials...
An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 2 Years
Conditions
Interventions
Gilenya
Locations
6
Canada
University of British Columbia
Vancouver, British Columbia, Canada
Dalhousie University Multiple Sclerosis Research Unit
Halifax, Nova Scotia, Canada
Ottawa General Hospital
Ottawa, Ontario, Canada
Clinique Neuro Rive-Sud
Greenfield Park, Quebec, Canada
Montreal Neurological Institute
Montreal, Quebec, Canada
Centre hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada
Start Date
November 1, 2012
Primary Completion Date
November 1, 2017
Completion Date
October 30, 2018
Last Updated
November 9, 2018
Lead Sponsor
McGill University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions